The DOI matches its Crossref record; 118 of the 123 references it cites were found in a registry or an index; 16 of the 51 sources its claims cite were checked for support.
Fenofibrate and Metabolic Syndrome
Open accessAbstract
The fibric acid derivative, fenofibrate (FF) has been used in the US since 1998 to manage patients with dyslipidemia. Typical changes in serum lipids as result a of FF treatment include clinically important mean reductions of serum triglycerides (TG) by a mean change of -93.7 mg/dL (-39.3%), increases of high density lipoprotein cholesterol (HDLC) by +5.5 mg/dL (+12.4%), and reductions in low density lipoprotein cholesterol (LDLC) by -17.9 mg/dL (-12.3%). The greatest reductions in serum TG are usually observed in subjects with elevated baseline TGs including those with the metabolic syndrome (MetS). Although statins remain the mainstay of therapy for most dyslipidemic patients, their combined use with FF would be expected to address residual risk resulting from less than optimal TG and HDLC levels in such patients. Clinical trials examining the cardiovascular benefits of FF alone or combined with statins have produced mixed results. These observations underscore our lack of understanding of which patients may benefit from FF therapy and which do not. Although FF's basic mechanism of action is known to involve PPAR-alpha agonist activity resulting in altered transcription of several genes, the actual genetic bases for variability in lipid response is poorly understood. Studies, such as our GOLDN study and others designed to better understand the genetic determinants of variability in the response to FF treatment and lipid levels. As a result several important genetic determinants of lipid levels have been identified. For example, in the GOLDN study SNPs from different genes were significantly associated with baseline lipid levels before treatment (APOA5- rs662799, rs3135506; APOC3- rs5128, rs2854117, rs4520); APOA4- rs5104; PPARA- rs9626730, rs135543, rs11703495; LPL- rs1801177), after treatment PPARA- rs11708495; LPL- rs1801177, and appeared to modulate overall response to FF treatment (NOS3- rs1799983). In this article, we will review the literature leading up to the contemporary use of FF as an agent to manage patients with dyslipidemia and focus on emerging understanding of the genetic variability in response to FF treatment. On the basis of the available evidence, we conclude that FF is of benefit in the treatment of dyslipidemia, especially among those with MetS. However, more work is needed to specifically identify which individuals derive a benefit from FF administration in terms of clinical outcomes and which do not - particularly in the context of type 2 diabetes.
Overview
CoChat Summary
TL;DR
This review concludes that fenofibrate benefits dyslipidemia, especially in metabolic syndrome, but which patients derive clinical outcome benefit remains unclear. It summarizes fenofibrate’s lipid effects, major trials, and GOLDN genetic associations with lipid response.
Key findings
- In a review of 15 clinical trials using TriCor-brand fenofibrate, mean changes were triglycerides −93.7 mg/dL (−39.3%), LDL cholesterol −17.9 mg/dL (−12.3%), and HDL cholesterol +5.5 mg/dL (+12.4%).
- In GOLDN, fenofibrate 160 mg once daily for 3–4 weeks decreased plasma triglycerides from an average 145 mg/dL to 91 mg/dL (−37.2%); subjects with metabolic syndrome had a greater triglyceride change, −108.3 mg/dL (−43.2%), than non-MetS subjects, −34.5 mg/dL (−31.4%).
- Baseline lipid associations included SNPs in APOA5 (rs662799, rs3135506), APOC3 (rs5128, rs2854117, rs4520), APOA4 (rs5104), PPARA (rs9626730, rs135543, rs11703495), and LPL (rs1801177); after treatment, PPARA rs11708495 and LPL rs1801177 remained associated, and NOS3 rs1799983 appeared to modulate overall response.
- Clinical outcome trials were mixed: FIELD (9,795 type 2 diabetes subjects) showed a 24% reduction in nonfatal myocardial infarction with fenofibrate versus placebo (p=0.01) but a non-significant increase in coronary heart disease mortality (p=0.22); ACCORD (5,518 type 2 diabetes patients on simvastatin) found no overall improvement in primary or secondary cardiovascular endpoints with added fenofibrate, with possible subgroup interactions by sex (P=0.01) and high-TG/low-HDL subgroup (P=0.057).
Methods
- Narrative literature review plus original GOLDN analyses. GOLDN was a clinical familial study with a fenofibrate treatment arm and a fat-load meal arm; the maximal sampled population was 1,107 white subjects with no missing phenotypes on 10 traits, treated with fenofibrate 160 mg once daily for 3–4 weeks.
- Candidate SNP association testing used 115 SNPs from 29 candidate genes, with multivariate factor analysis and random coefficients growth curves on repeated measures; the Bonferroni threshold was p=0.0004, and top findings were tested against LDL cholesterol, HDL cholesterol, and triglycerides.
- The authors also reviewed 15 clinical trials using TriCor-brand fenofibrate to summarize lipid changes.
Limitations
- The paper states that GOLDN’s 3–4 week treatment period does not allow judgment of long-term fenofibrate effects on clinical outcomes such as morbidity and mortality.
- The paper states that its candidate-gene approach had modest contribution to lipid profile change and that there have been limited outcome trials using fenofibrate as the study drug; fenofibrate use in type 2 diabetes was “not systematically evaluated” and produced mixed results.
- Evident from the text: as a narrative review, it does not report a systematic search or meta-analysis, and conclusions about clinical benefit rely on heterogeneous trials and subgroup findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 1 Not valid · 21 Not checked · 26 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The greatest reductions in serum TG are usually observed in subjects with elevated baseline TG including those with the metabolic syndrome (MetS).”
- Also stated in: § 2. FENOFIBRATE MONOTHERAPY · hedged
“For instance, individuals receiving FF, with highest baseline TG and lowest HDLC seem to demonstrate the greatest benefit in terms of improving their lipid profiles compared to those with only modest elevations in baseline TG and near normal baseline HDLC values [1].”
§ Fenofibrate and Metabolic Syndrome > Abstract
What the sources say
- Partly supportedcites [1] Scott R Best J Forder P Taskinen MR Simes J Barter P Keech A FIELD Study Investigators 2005 Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate Cardiovasc Diabetol 4 13 16111499 PMC1266033 sourceExperimental — accuracy not yet measured
The Results (page unavailable) report a 26% average triglyceride reduction after six weeks of fenofibrate and state that 84% of participants met metabolic-syndrome criteria. They do not compare triglyceride reductions by baseline triglyceride level or metabolic-syndrome status, so the claim that these subjects usually have the greatest reductions is not supported. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 2. FENOFIBRATE MONOTHERAPY · hedged
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Specifically, the five year FIELD Study, which evaluated 9,795 subjects with type 2 diabetes who were 50–75 years of age, demonstrated a reduction of 24% of non-fatal myocardial infraction (MI) for those receiving FF-compared to placebo (p=0.01).”
§ Fenofibrate and Metabolic Syndrome > 2. FENOFIBRATE MONOTHERAPY
What the sources say
- Partly supportedcites [46] Scott R O’Brien R Fulcher G Pardy C D’Emden M Tse D Taskinen MR Ehnholm C Keech A 2009 Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 493 498 18984774 PMC2646035 sourceExperimental — accuracy not yet measured
The FIELD study description (p. 1) confirms 9,795 participants with type 2 diabetes followed for an average of five years. The treatment results (p. 3) report an 11% reduction in total cardiovascular events with fenofibrate, but our copy does not report a 24% reduction in nonfatal myocardial infarction at p=0.01 or establish the stated age range (searched: nonfatal myocardial infarction, myocardial infarction, aged 50). (LLM, conf=0.87)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Clinical trials examining the cardiovascular benefits of FF alone or combined with statins have produced mixed results.”
- Also stated in: § 1. BACKGROUND SETTING OF FENOFIBRATE’S USE · plain
“The contemporary role of fibric acid derivatives and specifically FF, continues to be further refined as clinicians weigh the mixed outcomes from several large clinical trials [1, 2].”
§ Fenofibrate and Metabolic Syndrome > Abstract
What the sources say
- Partly supportedcites [1] Scott R Best J Forder P Taskinen MR Simes J Barter P Keech A FIELD Study Investigators 2005 Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate Cardiovasc Diabetol 4 13 16111499 PMC1266033 sourceExperimental — accuracy not yet measured
The Discussion (page not specified) reports that a fenofibrate trial found reduced progression of coronary atherosclerosis, supporting the claim that fenofibrate alone has been studied for cardiovascular benefit. It does not report mixed cardiovascular outcomes from fenofibrate trials or results from trials combining fenofibrate with statins; the Methods describe combination-treatment analyses as planned. (LLM, conf=0.82)
- Supportedcites [2] The ACCORD Study Group 2010 Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med [Epub ahead of print] PMC2879499 20228404 source
The paper reports that the FIELD fenofibrate trial did not reduce coronary heart disease events overall, although a post hoc analysis suggested benefit in a subgroup (Abstract > Conclusions; page unavailable). Its own fenofibrate-plus-simvastatin trial found no significant overall cardiovascular benefit, while subgroup analyses suggested possible benefit for some patients (Results > Clinical Outcomes; page unavailable). These findings support the description of mixed results. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. BACKGROUND SETTING OF FENOFIBRATE’S USE · plain
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“However this, as well as a lower rate of progression to albuminuria (p=0.002), reduction in need for laser therapy for retinopathy (p=0.0003) and reduction in need for coronary revascularization (p=0.003) conflicted with a non-significant increase in coronary heart disease mortality (p=0.22) [46].”
§ Fenofibrate and Metabolic Syndrome > 2. FENOFIBRATE MONOTHERAPY
What the sources say
- Could not verifycites [46] Scott R O’Brien R Fulcher G Pardy C D’Emden M Tse D Taskinen MR Ehnholm C Keech A 2009 Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 493 498 18984774 PMC2646035 sourceExperimental — accuracy not yet measured
The Effects of fenofibrate in marked dyslipidemia section (p. 3) reports a reduction in total cardiovascular events, not coronary heart disease mortality. A search of our copy for coronary deaths, mortality, and p=0.22 found no passage reporting the claimed mortality increase or its p-value. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Normally prescribed for patients with hypertension or heart failure, this angiotensin II receptor antagonist had no overall effect on cardiovascular mortality in spite of its benefits in reducing the risk of the incidence of diabetes [108].”
§ Fenofibrate and Metabolic Syndrome > 8. NEW CHALLENGES
What the sources say
- Supportedcites [108] The NAVIGATOR Study Group 2010 Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events N Engl J Med [Epub ahead of print] 20228403 source
The paper’s figure on death from any cause and cardiovascular causes reports no statistically significant difference in cardiovascular death between valsartan and placebo (hazard ratio 1.09; P=0.52). The Discussion also reports a reduced risk of diabetes in patients with impaired glucose tolerance, matching the citing sentence’s contrast. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
33 more claims · 6 with their cited sources checked
Create a free account to see all 62 claims and to verify the 8 references still open.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 14
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Fenofibrate and Metabolic Syndrome > 7. A CASE STUDY: FENOFIBRATE TREATMENT IN THE GOLDN STUDY AND GENETIC ASSOCIATIONS WITH METABOLIC SYNDROME FACTORS
“a meta p-value of 2.7×10−10 for the same polymorphism reported by Willer et al. [99]”
§ Fenofibrate and Metabolic Syndrome > References
“99. Qi L Liu S Rifai N Hunter D Hu FB 2007 Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes Atherosclerosis 192 204 210 16781717”
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961 · cited 1×
“Grundy et al. (2005) [3], specifically identifies reduced HDLC as a tertiary target but acknowledges there is not no specific goal to target increases in HDLC. Nonetheless, FF could be considered as an option for raising HDLC. FF has been demonstrated to have a somewhat variable effect raising HDLC…”
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581 · cited 1×
“and HDLC, one might expect that the establishment between FF drug therapy and risk for CHD would have been established long ago [74-78].”
Small sample inference for fixed effects from restricted maximum likelihood
Kenward, M. G., & Roger, J. H. (1997) · Biometrics · doi:10.2307/2533558 · Cited by 4,552
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · cited 2×
“With the publications of the Helsinki Heart Study using gemfibrozil in 1987, and the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) in 1999, both demonstrating reductions in coronary heart disease events [22, 23], a renewed interest in fibrates ensued.”
MethodEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Research works printed but not linked: 2
- [58]Wang TD Chen WJ Lin JW Cheng CC Chen MF Lee YT 2003 Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles Atherosclerosis 170 315 323 14612213
- [72]Rubins HB Robins SJ Collins D Fye CL Anderson JW Elam MB Faas FH Linares E Schaefer EJ Schectman G Wilt TJ Wittes J for The Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group 1999 Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 410 418 10438259
Cited by
Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models
Chen, Y., Hu, Y., Lin, M., Jenkins, A. J., Keech, A. C., Mott, R., Lyons, T. J., & Ma, J.-X. (2013) · Diabetes · doi:10.2337/db11-0413 · Cited by 183
“30 years for the treatment of dyslipidemia (16,17), is particularly effective in improving the lipid profile in hypertriglyceridemia and low HDL syndromes (18), and for reducing some cardiovascular events (19).”
BackgroundFenofibrate prevents skeletal muscle loss in mice with lung cancer
Goncalves, M. D., Hwang, S., Pauli, C., Murphy, C. J., Cheng, Z., Hopkins, B. D., Wu, D., Loughran, R. M., Emerling, B. M., Zhang, G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714703115 · Cited by 135
“The resulting clinical effect is a modest reduction in serum TG and TG-rich lipoproteins for which it has received Food and Drug Administration approval (55).”
BackgroundThe pharmacological management of metabolic syndrome
Larsen, J. R., Dima, L., Correll, C. U., & Manu, P. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1429910 · Cited by 132
“ticularly in overweight and hyperinsulinemic patients [91,92].”
Ferrari, R., Aguíar, C., Alegría, E., Bonadonna, R. C., Cosentino, F., Elisaf, M., Farnier, M., Ferrières, J., Filardi, P. P., Hâncu, N., et al. (2016) · European Heart Journal Supplements · doi:10.1093/eurheartj/suw009 · Cited by 107
“Furthermore, although clinical evidence comes from the diabetic population, patients with insulin resistance, or those who are overweight or obese, may also benefit from fenofibrate treatment.(39,40) The meta-analysis conducted by Sacks et al.”
BackgroundGraugnard, D. E., Moyes, K. M., Trevisi, E., Khan, M. J., Keisler, D. H., Drackley, J. K., Bertoni, G., & Loor, J. J. (2012) · Journal of Dairy Science · doi:10.3168/jds.2012-5676 · Cited by 119
Metadata
- Authors
- T. Kraja, A., A. Province, M., J. Straka, R., M. Ordovas, J., B. Borecki, I., & K. Arnett, D.
- Venue
- Endocrine, Metabolic & Immune Disorders - Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-06-01
- Volume
- 10
- Issue
- 2
- Pages
- 138-148
- ISSN
- 1871-5303 (ISSN-L)
- PMC
- PMC5278640
- OpenAlex
- W2114747205
- Semantic Scholar
- 186fedb3e486c44f8b5f90ab2ebf920ef65bb72e
- Cited by
- 40
- References
- 123
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 2 · 2021: 1 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 3 · 2014: 4 · 2013: 3 · 2012: 12
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Metabolic & Immune Disorders - Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL09135701A1, R01HL091357)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- fenofibrate, metabolic syndrome, dyslipidemia, PPARα agonist, single nucleotide polymorphisms, APOA5, apolipoprotein C-III, APOA4, PPARα, lipoprotein lipase, NOS3, triglycerides, HDL cholesterol, LDL cholesterol, statin combination therapy
- MeSH terms
- Hypolipidemic Agents, Diabetes Mellitus, Type 2, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Fenofibrate, Triglycerides, Hypertriglyceridemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Metabolic Syndrome, PPAR alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fenofibrate and Metabolic Syndrome. https://app.cochat.ai/papers/10.2174/187153010791213047
- The paper
- T. Kraja, A., A. Province, M., J. Straka, R., M. Ordovas, J., B. Borecki, I., & K. Arnett, D. (2010). Fenofibrate and Metabolic Syndrome. Endocrine, Metabolic & Immune Disorders - Drug Targets. https://doi.org/10.2174/187153010791213047
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.